# US 2022/0031750 A1 · Dimerizing agent regulated immunoreceptor complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031750 A1
- Document ID: US20220031750A1
- Status: Published application
- Kind: A1
- Application number: 17/312,120
- Filed: 2019-12-13
- Published: 2022-02-03
- Earliest claimed: 2018-12-14
- Assignees: bluebird bio, Inc.
- Applicants: bluebird bio, Inc.
- Inventors: JORDAN JARJOUR; ALEXANDER ASTRAKHAN; WAI-HANG LEUNG
- Web page: https://patentgrep.com/patent/US20220031750A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C12N 5/0636: {T lymphocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 2501/505: CD4; CD8
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

## Claims

### Claim 1

A non-natural cell comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof; a first transmembrane domain; a first costimulatory domain; and/or a primary signaling domain; and
(b) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a second costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the first and second multimerization domains.

### Claim 2 (depends on 1)

The non-natural cell of claim 1, wherein the first and second multimerization domains are different.

### Claim 3 (depends on 1, 2)

The non-natural cell of claim 1 or claim 2, wherein the first and second costimulatory domains are different.

### Claim 4 (depends on 1, 2, 3)

The non-natural cell of any one of claims 1 to 3, wherein the first multimerization domain and the second multimerization domain associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A (FKCsA) or a derivative thereof, and trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The non-natural cell of any one of claims 1 to 4, wherein the first multimerization domain and the second multimerization domain are a pair selected from the group consisting of: FKBP and FKBP-rapamycin binding (FRB), FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYR1-like 1 (PYL1) and abscisic acid insensitive 1 (ABI1).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The non-natural cell of any one of claims 1 to 5, wherein the first multimerization domain comprises an FKBP polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The non-natural cell of any one of claims 1 to 5, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP polypeptide or variant thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The non-natural cell of any one of claims 1 to 7, wherein the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The non-natural cell of any one of claims 1 to 8, wherein the first and second multimerization domains are selected from FRB T2098L and FKBP12; and the bridging factor is sirolimus or AP21967.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The non-natural cell of any one of claims 1 to 9, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, CD278, amnionless (AMN), and programmed cell death 1 (PDCD1).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The non-natural cell of any one of claims 1 to 10, wherein the first transmembrane domain and the second transmembrane domain are independently selected from the group consisting of: a CD4 transmembrane domain, a CD8α transmembrane domain, and an AMN transmembrane domain.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The non-natural cell of any one of claims 1 to 11, wherein the first transmembrane domain and the second transmembrane domain are different.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The non-natural cell of any one of claims 1 to 12, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The non-natural cell of any one of claims 1 to 13, wherein the first and second costimulatory domain are independently selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAP10), Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2, TNFRS14, TNFRS18, TNFRS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The non-natural cell of any one of claims 1 to 14, wherein the first costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137 and the second costimulatory domain is isolated from CD28, CD278, TNFRS14, TNFRS18, TNFRS25, OX40 or TNFR2.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The non-natural cell of any one of claims 1 to 15, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from OX40 or TNFR2.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The non-natural cell of any one of claims 1 to 16, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from OX40.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The non-natural cell of any one of claims 1 to 16, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from TNFR2.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The non-natural cell of any one of claims 1 to 18, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The non-natural cell of any one of claims 1 to 19, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The non-natural cell of any one of claims 1 to 20, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof, a receptor ectodomain, or a ligand.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The non-natural cell of any one of claims 1 to 21, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The non-natural cell of any one of claims 1 to 22, wherein the extracellular binding domain comprises a humanized antibody or antigen binding fragment thereof.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The non-natural cell of any one of claims 1 to 22, wherein the extracellular binding domain comprises a human antibody or antigen binding fragment thereof.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The non-natural cell of any one of claims 1 to 24, wherein the extracellular binding domain comprises an scFv.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The non-natural cell of any one of claims 1 to 23, wherein the extracellular binding domain comprises one or more camelid VHH antibodies.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The non-natural cell of any one of claims 1 to 26, wherein the extracellular binding domain binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The non-natural cell of any one of claims 1 to 27, wherein the extracellular binding domain binds an antigen selected from the group consisting of: alpha folate receptor (FRα), αvβ6 integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), claudin 6, (CLDN6), claudin 18 isoform 2 (CLDN18.2), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), delta like canonical Notch ligand 3 (DLL3), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), epithelial cell adhesion molecule (EPCAM), ephrin type-A receptor 2 (EPHA2), erb-b2 receptor tyrosine kinase 4 (ERBB4), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AchR), ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), HER2 p95, IL-10Rα, IL-13Rα2, Kappa, cancer/testis antigen 2 (LAGE-1A), Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), melanoma antigen gene (MAGE)-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, melanoma antigen recognized by T cells 1 (MelanA or MART1), Mesothelin (MSLN), MUC1, MUC16, MHC class I chain related proteins A (MICA), MHC class I chain related proteins B (MICB), neural cell adhesion molecule (NCAM), cancer/testis antigen 1 (NY-ESO-1), polysialic acid; placenta-specific 1 (PLAC1), preferentially expressed antigen in melanoma (PRAME), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X breakpoint 2 (SSX2), Survivin, tumor associated glycoprotein 72 (TAG72), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), trophoblast glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, vascular endothelial growth factor receptor 2 (VEGFR2), and Wilms tumor 1 (WT-1).

### Claim 29

A non-natural cell comprising:
(a) a first polypeptide comprising: an FK506 binding protein (FKBP) multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP-rapamycin binding (FRB) multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 30

A non-natural cell comprising:
(a) a first polypeptide comprising: an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 31

A non-natural cell comprising:
(a) a first polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 32

A non-natural cell comprising:
(a) a first polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 33 (depends on 29, 30, 31, 32)

The non-natural cell of any one of claims 29 to 32, wherein the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The non-natural cell of any one of claims 29 to 33, wherein the FRB multimerization domain is FRB T2098L; the FKBP multimerization domain is FKBP12; and the bridging factor is sirolimus or AP21967.

### Claim 35 (depends on 29, 30, 31, 32, 33, 34)

The non-natural cell of any one of claims 29 to 34, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, AMN, and PDCD1.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The non-natural cell of any one of claims 29 to 35, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: a CD4 transmembrane domain and a CD8α transmembrane domain.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

The non-natural cell of any one of claims 29 to 36, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The non-natural cell of any one of claims 29 to 37, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAP10), Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2, TNFRS14, TNFRS18, TNFRS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The non-natural cell of any one of claims 29 to 38, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137.

### Claim 40 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The non-natural cell of any one of claims 29 to 39, wherein the costimulatory domain is isolated from a CD137 costimulatory molecule.

### Claim 41 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The non-natural cell of any one of claims 29 to 40, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 42 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The non-natural cell of any one of claims 29 to 41, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 43 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The non-natural cell of any one of claims 29 to 42, wherein the antibody or antigen binding fragment thereof selected is from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 44 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The non-natural cell of any one of claims 29 to 43, wherein the antibody or antigen binding fragment thereof is human or humanized.

### Claim 45 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The non-natural cell of any one of claims 29 to 44, wherein the antibody or antigen binding fragment thereof comprises an scFv or one or more camelid VHH antibodies.

### Claim 46 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The non-natural cell of any one of claims 29 to 45, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 47 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The non-natural cell of any one of claims 29 to 46, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 48 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The non-natural cell of any one of claims 29 to 47, wherein the antibody or antigen binding fragment thereof binds BCMA, B7-H3, CD19, CD20, CD22, CD33, CD79A, CD79B, and/or EGFRvIII.

### Claim 49 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds BCMA.

### Claim 50 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds CD19.

### Claim 51 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds CD20 or CD22.

### Claim 52 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds B7-H3.

### Claim 53 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds CD33.

### Claim 54 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds CD79A.

### Claim 55 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds CD79B.

### Claim 56 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The non-natural cell of any one of claims 29 to 48, wherein the antibody or antigen binding fragment thereof binds EGFRvIII.

### Claim 57

A non-natural cell comprising:
(a) a first polypeptide comprising: an FKBP12 multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB T2098L multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and a TNFR2 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 58

A non-natural cell comprising:
(a) a first polypeptide comprising: an FKBP12 multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB T2098L multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and an OX40 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 59

A non-natural cell comprising:
(a) a first polypeptide comprising: an FRB T2098L multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP12 multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and a TNFR2 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 60

A non-natural cell comprising:
(a) a first polypeptide comprising: an FRB T2098L multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain; and
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP12 multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and an OX40 costimulatory domain;
wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 61 (depends on 57, 58, 59, 60)

The non-natural cell of any one of claims 57 to 60, wherein the bridging factor is AP21967 or sirolimus.

### Claim 62 (depends on 57, 58, 59, 60, 61)

The non-natural cell of any one of claims 57 to 61, wherein the antibody or antigen binding fragment thereof selected is from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 63 (depends on 57, 58, 59, 60, 61, 62)

The non-natural cell of any one of claims 57 to 62, wherein the antibody or antigen binding fragment thereof is human or humanized.

### Claim 64 (depends on 57, 58, 59, 60, 61, 62, 63)

The non-natural cell of any one of claims 57 to 63, wherein the antibody or antigen binding fragment thereof comprises an scFv or one or more camelid VHH antibodies.

### Claim 65 (depends on 57, 58, 59, 60, 61, 62, 63, 64)

The non-natural cell of any one of claims 57 to 64, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 66 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65)

The non-natural cell of any one of claims 57 to 65, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 67 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The non-natural cell of any one of claims 57 to 66, wherein the antibody or antigen binding fragment thereof binds BCMA, B7-H3, CD19, CD20, CD22, CD33, CD79A, CD79B, and/or EGFRvIII.

### Claim 68 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds BCMA.

### Claim 69 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds CD19.

### Claim 70 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds CD20 or CD22.

### Claim 71 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds B7H3.

### Claim 72 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds CD33.

### Claim 73 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds CD79A.

### Claim 74 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds CD79B.

### Claim 75 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The non-natural cell of any one of claims 57 to 67, wherein the antibody or antigen binding fragment thereof binds EGFRvIII, optionally wherein the antibody is EGFR806 or an antigen binding fragment thereof.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The non-natural cell of any one of claims 1 to 75, wherein the multimerization domains localize extracellularly when of the first polypeptide and the second polypeptide are expressed.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The non-natural cell of any one of claims 1 to 76, wherein the cell is a hematopoietic cell.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The non-natural cell of any one of claims 1 to 76, wherein the cell is a T cell.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The non-natural cell of any one of claims 1 to 76, wherein the cell is a CD3+, CD4+, and/or CD8+ cell.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The non-natural cell of any one of claims 1 to 76, wherein the cell is an immune effector cell.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The non-natural cell of any one of claims 1 to 76, wherein the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The non-natural cell of any one of claims 1 to 76, wherein the cell is a natural killer (NK) cell or natural killer T (NKT) cell.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The non-natural cell of any one of claims 1 to 82, wherein the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.

### Claim 84

A fusion polypeptide comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof; a first transmembrane domain; a first costimulatory domain; and/or a primary signaling domain; and
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a second costimulatory domain.

### Claim 85 (depends on 84)

The fusion polypeptide of claim 84, wherein the first and second multimerization domains are different.

### Claim 86 (depends on 84, 85)

The fusion polypeptide of claim 84 or claim 85, wherein the first and second costimulatory domains are different.

### Claim 87 (depends on 84, 85, 86)

The fusion polypeptide of any one of claims 84 to 86, wherein the first multimerization domain and the second multimerization domain associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A (FKCsA) or a derivative thereof, and trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof.

### Claim 88 (depends on 84, 85, 86, 87)

The fusion polypeptide of any one of claims 84 to 87, wherein the first multimerization domain and the second multimerization domain are a pair selected from the group consisting of: FKBP and FKBP-rapamycin binding (FRB), FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYR1-like 1 (PYL1) and abscisic acid insensitive 1 (ABI1).

### Claim 89 (depends on 84, 85, 86, 87, 88)

The fusion polypeptide of any one of claims 84 to 88, wherein the first multimerization domain comprises an FKBP polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.

### Claim 90 (depends on 84, 85, 86, 87, 88)

The fusion polypeptide of any one of claims 84 to 88, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP polypeptide or variant thereof.

### Claim 91 (depends on 84, 85, 86, 87, 88, 89, 90)

The fusion polypeptide of any one of claims 84 to 90, wherein the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.

### Claim 92 (depends on 84, 85, 86, 87, 88, 89, 90, 91)

The fusion polypeptide of any one of claims 84 to 91, wherein the first and second multimerization domains are selected from FRB T2098L and FKBP12; and the bridging factor is sirolimus or AP21967.

### Claim 93 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92)

The fusion polypeptide of any one of claims 84 to 92, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, CD278, amnionless (AMN), and programmed cell death 1 (PDCD1).

### Claim 94 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The fusion polypeptide of any one of claims 84 to 93, wherein the first transmembrane domain and the second transmembrane domain are independently selected from the group consisting of: a CD4 transmembrane domain, a CD8α transmembrane domain, and an AMN transmembrane domain.

### Claim 95 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The fusion polypeptide of any one of claims 84 to 94, wherein the first transmembrane domain and the second transmembrane domain are different.

### Claim 96 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The fusion polypeptide of any one of claims 84 to 95, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 97 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The fusion polypeptide of any one of claims 84 to 96, wherein the first and second costimulatory domain are independently selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAP10), Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2, TNFRS14, TNFRS18, TNFRS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).

### Claim 98 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The fusion polypeptide of any one of claims 84 to 97, wherein the first costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137 and the second costimulatory domain is isolated from CD28, CD278, TNFRS14, TNFRS18, TNFRS25, OX40 or TNFR2.

### Claim 99 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The fusion polypeptide of any one of claims 84 to 98, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from OX40 or TNFR2.

### Claim 100 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The fusion polypeptide of any one of claims 84 to 99, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from OX40.

### Claim 101 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The fusion polypeptide of any one of claims 84 to 99, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from TNFR2.

### Claim 102 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The fusion polypeptide of any one of claims 84 to 101, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 103 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The fusion polypeptide of any one of claims 84 to 102, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 104 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The fusion polypeptide of any one of claims 84 to 103, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof, a receptor ectodomain, or a ligand.

### Claim 105 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The fusion polypeptide of any one of claims 84 to 104, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 106 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The fusion polypeptide of any one of claims 84 to 105, wherein the extracellular binding domain comprises a humanized antibody or antigen binding fragment thereof.

### Claim 107 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The fusion polypeptide of any one of claims 84 to 105, wherein the extracellular binding domain comprises a human antibody or antigen binding fragment thereof.

### Claim 108 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The fusion polypeptide of any one of claims 84 to 107, wherein the extracellular binding domain comprises an scFv.

### Claim 109 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The fusion polypeptide of any one of claims 84 to 107, wherein the extracellular binding domain comprises one or more camelid VHH antibodies.

### Claim 110 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The fusion polypeptide of any one of claims 84 to 109, wherein the extracellular binding domain binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 111 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The fusion polypeptide of any one of claims 84 to 110, wherein the extracellular binding domain binds an antigen selected from the group consisting of: FRα, αvβ6 integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 112

A fusion polypeptide comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain.

### Claim 113

A fusion polypeptide comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain.

### Claim 114 (depends on 112, 113)

The fusion polypeptide of claim 112 or claim 113, wherein the first and second multimerization domains are the same.

### Claim 115 (depends on 112, 113)

The fusion polypeptide of claim 112 or claim 113, wherein the first and second multimerization domains are different.

### Claim 116 (depends on 112, 113, 114, 115)

The fusion polypeptide of claims 112 to 115, wherein the first multimerization domain and the second multimerization domain associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, ABA or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FKCsA or a derivative thereof, and SLF or a derivative thereof.

### Claim 117 (depends on 112, 113, 114, 115, 116)

The fusion polypeptide of claims 112 to 116, wherein the first multimerization domain and the second multimerization domain are a pair selected from the group consisting of: FKBP and FRB, FKBP and calcineurin, FKBP and cyclophilin, FKBP and DHFR, calcineurin and cyclophilin, and PYL1 and ABI1.

### Claim 118 (depends on 112, 113, 114, 115, 116, 117)

The fusion polypeptide of claims 112 to 117, wherein the first multimerization domain comprises an FKBP polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.

### Claim 119 (depends on 112, 113, 114, 115, 116, 117)

The fusion polypeptide of claims 112 to 117, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP polypeptide or variant thereof.

### Claim 120 (depends on 112, 113, 114, 115, 116, 117, 118, 119)

The fusion polypeptide of claims 112 to 119, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, AMN, and PDCD1.

### Claim 121 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120)

The fusion polypeptide of claims 112 to 120, wherein the first transmembrane domain and the second transmembrane domain are independently selected from the group consisting of: a CD4 transmembrane domain and a CD8α transmembrane domain.

### Claim 122 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The fusion polypeptide of claims 112 to 121, wherein the first transmembrane domain and the second transmembrane domain are the same.

### Claim 123 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The fusion polypeptide of claims 112 to 121, wherein the first transmembrane domain and the second transmembrane domain are different.

### Claim 124 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The fusion polypeptide of claims 112 to 123, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 125 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The fusion polypeptide of claims 112 to 124, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, SLP76, TRAT1, TNFR2, TNFRS14, TNFRS18, TNFRS25, and ZAP70.

### Claim 126 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The fusion polypeptide of claims 112 to 125, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137.

### Claim 127 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

The fusion polypeptide of claims 112 to 126, wherein the costimulatory domain is isolated from a CD137 costimulatory molecule.

### Claim 128 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127)

The fusion polypeptide of claims 112 to 127, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 129 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)

The fusion polypeptide of claims 112 to 128, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 130 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129)

The fusion polypeptide of claims 112 to 129, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof, a receptor ectodomain, or a ligand.

### Claim 131 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

The fusion polypeptide of claims 112 to 130, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 132 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The fusion polypeptide of claims 112 to 131, wherein the extracellular binding domain comprises a humanized antibody or antigen binding fragment thereof.

### Claim 133 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The fusion polypeptide of claims 112 to 131, wherein the extracellular binding domain comprises a human antibody or antigen binding fragment thereof.

### Claim 134 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The fusion polypeptide of claims 112 to 133, wherein the extracellular binding domain comprises an scFv.

### Claim 135 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131)

The fusion polypeptide of claims 112 to 131, wherein the extracellular binding domain comprises one or more camelid VHH antibodies.

### Claim 136 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The fusion polypeptide of claims 112 to 135, wherein the extracellular binding domain binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 137 (depends on 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The fusion polypeptide of claims 112 to 136, wherein the extracellular binding domain binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 138

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain.

### Claim 139

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain.

### Claim 140

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain.

### Claim 141

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain.

### Claim 142 (depends on 138, 139, 140, 141)

The fusion polypeptide of any one of claims 138 to 141, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, AMN, and PDCD1.

### Claim 143 (depends on 138, 139, 140, 141, 142)

The fusion polypeptide of any one of claims 138 to 142, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: a CD4 transmembrane domain and a CD8α transmembrane domain.

### Claim 144 (depends on 138, 139, 140, 141, 142, 143)

The fusion polypeptide of any one of claims 138 to 143, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 145 (depends on 138, 139, 140, 141, 142, 143, 144)

The fusion polypeptide of any one of claims 138 to 144, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, SLP76, TRAT1, TNFR2, TNFRS14, TNFRS18, TNFRS25, and ZAP70.

### Claim 146 (depends on 138, 139, 140, 141, 142, 143, 144, 145)

The fusion polypeptide of any one of claims 138 to 145, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137.

### Claim 147 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146)

The fusion polypeptide of any one of claims 138 to 146, wherein the costimulatory domain is isolated from a CD137 costimulatory molecule.

### Claim 148 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147)

The fusion polypeptide of any one of claims 138 to 147, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 149 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148)

The fusion polypeptide of any one of claims 138 to 148, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 150 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149)

The fusion polypeptide of any one of claims 138 to 149, wherein the antibody or antigen binding fragment thereof selected is from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 151 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150)

The fusion polypeptide of any one of claims 138 to 150, wherein the antibody or antigen binding fragment thereof is human or humanized.

### Claim 152 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150)

The fusion polypeptide of any one of claims 138 to 150, wherein the antibody or antigen binding fragment thereof comprises an scFv or one or more camelid VHH antibodies.

### Claim 153 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152)

The fusion polypeptide of any one of claims 138 to 152, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 154 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The fusion polypeptide of any one of claims 138 to 153, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 155 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154)

The fusion polypeptide of any one of claims 138 to 154, wherein the antibody or antigen binding fragment thereof binds BCMA, B7-H3, CD19, CD20, CD22, CD33, CD79A, CD79B, and/or EGFRvIII.

### Claim 156 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds BCMA.

### Claim 157 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds CD19.

### Claim 158 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds CD20 or CD22.

### Claim 159 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds B7-H3.

### Claim 160 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds CD33.

### Claim 161 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds CD79A.

### Claim 162 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds CD79B.

### Claim 163 (depends on 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The fusion polypeptide of any one of claims 138 to 155, wherein the antibody or antigen binding fragment thereof binds EGFRvIII.

### Claim 164

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FKBP12 multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB T2098L multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and a TNFR2 costimulatory domain.

### Claim 165

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FKBP12 multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB T2098L multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and an OX40 costimulatory domain.

### Claim 166

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FRB T2098L multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP12 multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and a TNFR2 costimulatory domain.

### Claim 167

A fusion polypeptide comprising:
(a) a first polypeptide comprising: an FRB T2098L multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP12 multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and an OX40 costimulatory domain.

### Claim 168 (depends on 164, 165, 166, 167)

The fusion polypeptide of any one of claims 164 to 167, wherein the antibody or antigen binding fragment thereof selected is from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 169 (depends on 164, 165, 166, 167, 168)

The fusion polypeptide of any one of claims 164 to 168, wherein the antibody or antigen binding fragment thereof is human or humanized.

### Claim 170 (depends on 164, 165, 166, 167, 168, 169)

The fusion polypeptide of any one of claims 164 to 169, wherein the antibody or antigen binding fragment thereof comprises an scFv or one or more camelid VHH antibodies.

### Claim 171 (depends on 164, 165, 166, 167, 168, 169, 170)

The fusion polypeptide of any one of claims 164 to 170, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 172 (depends on 164, 165, 166, 167, 168, 169, 170, 171)

The fusion polypeptide of any one of claims 164 to 171, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 173 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172)

The fusion polypeptide of any one of claims 164 to 172, wherein the antibody or antigen binding fragment thereof binds BCMA, B7-H3, CD19, CD20, CD22, CD33, CD79A, CD79B, and/or EGFRvIII.

### Claim 174 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds BCMA.

### Claim 175 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds CD19.

### Claim 176 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds CD20 or CD22.

### Claim 177 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds B7-H3.

### Claim 178 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds CD33.

### Claim 179 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds CD79A.

### Claim 180 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds CD79B.

### Claim 181 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173)

The fusion polypeptide of any one of claims 164 to 173, wherein the antibody or antigen binding fragment thereof binds EGFRvIII, optionally wherein the antibody is EGFR806 or an antigen binding fragment thereof.

### Claim 182 (depends on 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The fusion polypeptide of any one of claims 164 to 181, wherein the multimerization domains localize extracellularly when of the first polypeptide and the second polypeptide are expressed.

### Claim 183 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The fusion polypeptide of any one of claims 84 to 182, wherein the polypeptide cleavage signal is a viral self-cleaving polypeptide.

### Claim 184 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183)

The fusion polypeptide of any one of claims 84 to 183, wherein the polypeptide cleavage signal is a viral self-cleaving 2A polypeptide.

### Claim 185 (depends on 84, 184)

The fusion polypeptide of any one of claims 84 to 184, wherein the polypeptide cleavage signal is a viral self-cleaving polypeptide selected from the group consisting of: a foot-and-mouth disease virus (FMDV) (F2A) peptide, an equine rhinitis A virus (ERAV) (E2A) peptide, a Thosea asigna virus (TaV) (T2A) peptide, a porcine teschovirus-1 (PTV-1) (P2A) peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.

### Claim 186 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 185)

A polynucleotide encoding the first or the second polypeptide of any one of claims 1 to 83 or the fusion polypeptide of any one of claims 84 to 185.

### Claim 187 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 185)

A cDNA encoding the first or the second polypeptide of any one of claims 1 to 83 or the fusion polypeptide of any one of claims 84 to 185.

### Claim 188 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 185)

An RNA encoding the first or the second polypeptide of any one of claims 1 to 83 or the fusion polypeptide of any one of claims 84 to 185.

### Claim 189 (depends on 186, 187, 188)

A vector comprising the polynucleotide of any one of claims 186 to 188.

### Claim 190 (depends on 189)

The vector of claim 189, wherein the vector is an expression vector.

### Claim 191 (depends on 189)

The vector of claim 189, wherein the vector is a transposon.

### Claim 192 (depends on 191)

The vector of claim 191, wherein the vector is a piggyBAC transposon or a Sleeping Beauty transposon.

### Claim 193 (depends on 189)

The vector of claim 189, wherein the vector is a viral vector.

### Claim 194 (depends on 193)

The vector of claim 193, wherein the vector is an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes virus vector, a vaccinia virus vector, or a retroviral vector.

### Claim 195 (depends on 194)

The vector of claim 194, wherein the retroviral vector is a lentiviral vector.

### Claim 196 (depends on 195)

The vector of claim 195, wherein the lentiviral vector is selected from the group consisting of: human immunodeficiency virus 1 (HIV-1); human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).

### Claim 197 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196)

A composition comprising the non-natural cell of any one of claims 1 to 83, the fusion polypeptide of any one of claims 84 to 185, the polynucleotide of any one of claims 186 to 188, or the vector of any one of claims 189 to 196.

### Claim 198 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196)

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the non-natural cell of any one of claims 1 to 83, the fusion polypeptide of any one of claims 84 to 185, the polynucleotide of any one of claims 186 to 188, or the vector of any one of claims 189 to 196.

### Claim 199 (depends on 197, 198)

A method of treating a subject in need thereof comprising administering the subject an effective amount of the composition of claim 197 or claim 198.

### Claim 200 (depends on 197, 198)

A method of treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith, comprising administering to the subject an effective amount of the composition of claim 197 or claim 198.

### Claim 201 (depends on 197, 198)

A method of treating a solid cancer comprising administering to the subject an effective amount of the composition of claim 197 or claim 198.

### Claim 202 (depends on 201)

The method of claim 201, wherein the solid cancer comprises liver cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, bladder cancer, brain cancer, sarcoma, head and neck cancer, bone cancer, thyroid cancer, kidney cancer, or skin cancer.

### Claim 203 (depends on 201, 202)

The method of claim 201 or claim 202, wherein the solid cancer is a pancreatic cancer, a lung cancer, or a breast cancer.

### Claim 204 (depends on 197, 198)

A method of treating a hematological malignancy comprising administering to the subject an effective amount of the composition of claim 197 or claim 198.

### Claim 205 (depends on 204)

The method of claim 204, wherein the hematological malignancy is a leukemia, lymphoma, or multiple myeloma.

### Claim 206

A polypeptide complex comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof; a first transmembrane domain; a first costimulatory domain; and/or a primary signaling domain; and
(b) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a second costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 207 (depends on 206)

The polypeptide complex of claim 206, wherein the first and second multimerization domains are different.

### Claim 208 (depends on 206, 207)

The polypeptide complex of claim 206 or claim 207, wherein the first and second costimulatory domains are different.

### Claim 209 (depends on 206, 207, 208)

The polypeptide complex of any one of claims 206 to 208, wherein the first multimerization domain and the second multimerization domain associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A (FKCsA) or a derivative thereof, and trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof.

### Claim 210 (depends on 206, 207, 208, 209)

The polypeptide complex of any one of claims 206 to 209, wherein the first multimerization domain and the second multimerization domain are a pair selected from the group consisting of: FKBP and FKBP-rapamycin binding (FRB), FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYR1-like 1 (PYL1) and abscisic acid insensitive 1 (ABI1).

### Claim 211 (depends on 206, 207, 208, 209, 210)

The polypeptide complex of any one of claims 206 to 210, wherein the first multimerization domain comprises an FKBP polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.

### Claim 212 (depends on 206, 207, 208, 209, 210, 211)

The polypeptide complex of any one of claims 206 to 211, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP polypeptide or variant thereof.

### Claim 213 (depends on 206, 207, 208, 209, 210, 211, 212)

The polypeptide complex of any one of claims 206 to 212, wherein the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.

### Claim 214 (depends on 206, 207, 208, 209, 210, 211, 212, 213)

The polypeptide complex of any one of claims 206 to 213, wherein the first and second multimerization domains are selected from FRB T2098L and FKBP12; and the bridging factor is sirolimus or AP21967.

### Claim 215 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214)

The polypeptide complex of any one of claims 206 to 214, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, CD278, amnionless (AMN), and programmed cell death 1 (PDCD1).

### Claim 216 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215)

The polypeptide complex of any one of claims 206 to 215, wherein the first transmembrane domain and the second transmembrane domain are independently selected from the group consisting of: a CD4 transmembrane domain, a CD8α transmembrane domain, and an AMN transmembrane domain.

### Claim 217 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216)

The polypeptide complex of any one of claims 206 to 216, wherein the first transmembrane domain and the second transmembrane domain are different.

### Claim 218 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217)

The polypeptide complex of any one of claims 206 to 217, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 219 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218)

The polypeptide complex of any one of claims 206 to 218, wherein the first and second costimulatory domain are independently selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAP10), Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2, TNFRS14, TNFRS18, TNFRS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).

### Claim 220 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219)

The polypeptide complex of any one of claims 206 to 219, wherein the first costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137 and the second costimulatory domain is isolated from CD28, CD278, TNFRS14, TNFRS18, TNFRS25, OX40 or TNFR2.

### Claim 221 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220)

The polypeptide complex of any one of claims 206 to 220, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from OX40 or TNFR2.

### Claim 222 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221)

The polypeptide complex of any one of claims 206 to 221, wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from OX40.

### Claim 223 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221)

The polypeptide complex of any one of claims 206 to 221 wherein the first costimulatory domain is isolated from CD137 and the second costimulatory domain is isolated from TNFR2.

### Claim 224 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223)

The polypeptide complex of any one of claims 206 to 223, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 225 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224)

The polypeptide complex of any one of claims 206 to 224, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 226 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225)

The polypeptide complex of any one of claims 206 to 225, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof, a receptor ectodomain, or a ligand.

### Claim 227 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226)

The polypeptide complex of any one of claims 206 to 226, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 228 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227)

The polypeptide complex of any one of claims 206 to 227, wherein the extracellular binding domain comprises a humanized antibody or antigen binding fragment thereof.

### Claim 229 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227)

The polypeptide complex of any one of claims 206 to 227, wherein the extracellular binding domain comprises a human antibody or antigen binding fragment thereof.

### Claim 230 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229)

The polypeptide complex of any one of claims 206 to 229, wherein the extracellular binding domain comprises an scFv.

### Claim 231 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229)

The polypeptide complex of any one of claims 206 to 229, wherein the extracellular binding domain comprises one or more camelid VHH antibodies.

### Claim 232 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231)

The polypeptide complex of any one of claims 206 to 231, wherein the extracellular binding domain binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 233 (depends on 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232)

The polypeptide complex of any one of claims 206 to 232, wherein the extracellular binding domain binds an antigen selected from the group consisting of: FRα, αvβ6 integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 234

A polypeptide complex comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 235

A polypeptide complex comprising:
(a) a first polypeptide comprising: a first multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an extracellular binding domain; a second multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 236 (depends on 234, 235)

The polypeptide complex of claim 234 or claim 235, wherein the first and second multimerization domains are the same.

### Claim 237 (depends on 234, 236)

The polypeptide complex of claim 234 or claim 236, wherein the first and second multimerization domains are different.

### Claim 238 (depends on 234, 235, 236, 237)

The polypeptide complex of any one of claims 234 to 237, wherein the first multimerization domain and the second multimerization domain associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, ABA or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FKCsA or a derivative thereof, and SLF or a derivative thereof.

### Claim 239 (depends on 234, 235, 236, 237, 238)

The polypeptide complex of any one of claims 234 to 238, wherein the first multimerization domain and the second multimerization domain are a pair selected from the group consisting of: FKBP and FRB, FKBP and calcineurin, FKBP and cyclophilin, FKBP and DHFR, calcineurin and cyclophilin, and PYL1 and ABI1.

### Claim 240 (depends on 234, 235, 236, 237, 238, 239)

The polypeptide complex of any one of claims 234 to 239, wherein the first multimerization domain comprises an FKBP polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.

### Claim 241 (depends on 234, 235, 236, 237, 238, 239)

The polypeptide complex of any one of claims 234 to 239, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP polypeptide or variant thereof.

### Claim 242 (depends on 234, 235, 236, 237, 238, 239, 240, 241)

The polypeptide complex of any one of claims 234 to 241, wherein the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.

### Claim 243 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242)

The polypeptide complex of any one of claims 234 to 242, wherein the first and second multimerization domains are selected from FRB T2098L and FKBP12; and the bridging factor is sirolimus or AP21967.

### Claim 244 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243)

The polypeptide complex of any one of claims 234 to 243, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, AMN, and PDCD1.

### Claim 245 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244)

The polypeptide complex of any one of claims 234 to 244, wherein the first transmembrane domain and the second transmembrane domain are independently selected from the group consisting of: a CD4 transmembrane domain and a CD8α transmembrane domain.

### Claim 246 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245)

The polypeptide complex of any one of claims 234 to 245, wherein the first transmembrane domain and the second transmembrane domain are the same.

### Claim 247 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245)

The polypeptide complex of any one of claims 234 to 245, wherein the first transmembrane domain and the second transmembrane domain are different.

### Claim 248 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247)

The polypeptide complex of any one of claims 234 to 247, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 249 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248)

The polypeptide complex of any one of claims 234 to 248, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, SLP76, TRAT1, TNFR2, and ZAP70.

### Claim 250 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249)

The polypeptide complex of any one of claims 234 to 249, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137.

### Claim 251 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250)

The polypeptide complex of any one of claims 234 to 250, wherein the costimulatory domain is isolated from a CD137 costimulatory molecule.

### Claim 252 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251)

The polypeptide complex of any one of claims 234 to 251, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 253 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252)

The polypeptide complex of any one of claims 234 to 252, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 254 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253)

The polypeptide complex of any one of claims 234 to 253, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof, a receptor ectodomain, or a ligand.

### Claim 255 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254)

The polypeptide complex of any one of claims 234 to 254, wherein the extracellular binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 256 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255)

The polypeptide complex of any one of claims 234 to 255, wherein the extracellular binding domain comprises a humanized antibody or antigen binding fragment thereof.

### Claim 257 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255)

The polypeptide complex of any one of claims 234 to 255, wherein the extracellular binding domain comprises a human antibody or antigen binding fragment thereof.

### Claim 258 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257)

The polypeptide complex of any one of claims 234 to 257, wherein the extracellular binding domain comprises an scFv.

### Claim 259 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255)

The polypeptide complex of any one of claims 234 to 255, wherein the extracellular binding domain comprises one or more camelid VHH antibodies.

### Claim 260 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259)

The polypeptide complex of any one of claims 234 to 259, wherein the extracellular binding domain binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 261 (depends on 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260)

The polypeptide complex of any one of claims 234 to 260, wherein the extracellular binding domain binds an antigen selected from the group consisting of: FRα, αvβ6 integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 262

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 263

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 264

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP multimerization domain polypeptide or variant thereof; a second transmembrane domain; and an OX40 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 265

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a first transmembrane domain; a costimulatory domain; and/or a primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP multimerization domain polypeptide or variant thereof; a second transmembrane domain; and a TNFR2 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 266 (depends on 262, 263, 264, 265)

The polypeptide complex of any one of claims 262 to 265, wherein the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.

### Claim 267 (depends on 262, 263, 264, 265, 266)

The polypeptide complex of any one of claims 262 to 266, wherein the FRB multimerization domain is FRB T2098L; the FKBP multimerization domain is FKBP12; and the bridging factor is sirolimus or AP21967.

### Claim 268 (depends on 262, 263, 264, 265, 266, 267)

The polypeptide complex of any one of claims 262 to 267, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: alpha, beta, gamma, or delta chain of the T-cell receptor, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD154, AMN, and PDCD1.

### Claim 269 (depends on 262, 263, 264, 265, 266, 267, 268)

The polypeptide complex of any one of claims 262 to 268, wherein the first transmembrane domain and the second transmembrane domain are independently selected from a polypeptide selected from the group consisting of: a CD4 transmembrane domain and a CD8α transmembrane domain.

### Claim 270 (depends on 262, 263, 264, 265, 266, 267, 268, 269)

The polypeptide complex of any one of claims 262 to 269, wherein the costimulatory domain and/or the primary signaling domain comprise an immunoreceptor tyrosine activation motif (ITAM).

### Claim 271 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270)

The polypeptide complex of any one of claims 262 to 270, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, SLP76, TRAT1, TNFR2, and ZAP70.

### Claim 272 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271)

The polypeptide complex of any one of claims 262 to 271, wherein the costimulatory domain is isolated from a costimulatory molecule selected from the group consisting of: CD28, CD134, and CD137.

### Claim 273 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272)

The polypeptide complex of any one of claims 262 to 272, wherein the costimulatory domain is isolated from a CD137 costimulatory molecule.

### Claim 274 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273)

The polypeptide complex of any one of claims 262 to 273, wherein the primary signaling domain isolated from a polypeptide selected from the group consisting of: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

### Claim 275 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274)

The polypeptide complex of any one of claims 262 to 274, wherein the primary signaling domain is isolated from a CD3ζ polypeptide.

### Claim 276 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275)

The polypeptide complex of any one of claims 262 to 275, wherein the antibody or antigen binding fragment thereof selected is from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 277 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276)

The polypeptide complex of any one of claims 262 to 276, wherein the antibody or antigen binding fragment thereof is human or humanized.

### Claim 278 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277)

The polypeptide complex of any one of claims 262 to 277, wherein the antibody or antigen binding fragment thereof comprises an scFv or one or more camelid VHH antibodies.

### Claim 279 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278)

The polypeptide complex of any one of claims 262 to 278, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 280 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279)

The polypeptide complex of any one of claims 262 to 279, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 281 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280)

The polypeptide complex of any one of claims 262 to 280, wherein the antibody or antigen binding fragment thereof binds BCMA, B7-H3, CD19, CD20, CD22, CD33, CD79A, CD79B, and/or EGFRvIII.

### Claim 282 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds BCMA.

### Claim 283 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds CD19.

### Claim 284 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds CD20 or CD22.

### Claim 285 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds B7-H3.

### Claim 286 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds CD33.

### Claim 287 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds CD79A.

### Claim 288 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds CD79B.

### Claim 289 (depends on 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281)

The polypeptide complex of any one of claims 262 to 281, wherein the antibody or antigen binding fragment thereof binds EGFRvIII.

### Claim 290

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FKBP12 multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB T2098L multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and a TNFR2 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 291

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FKBP12 multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FRB T2098L multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and an OX40 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 292

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FRB T2098L multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP12 multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and a TNFR2 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 293

A polypeptide complex comprising:
(a) a first polypeptide comprising: an FRB T2098L multimerization domain polypeptide or variant thereof; a CD8α transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain;
(b) a second polypeptide comprising: an antibody or antigen binding fragment thereof; an FKBP12 multimerization domain polypeptide or variant thereof; a CD4 transmembrane domain; and an OX40 costimulatory domain; and
(c) a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.

### Claim 294 (depends on 290, 291, 292, 293)

The polypeptide complex of any one of claims 290 to 293, wherein the bridging factor is AP21967 or sirolimus.

### Claim 295 (depends on 290, 291, 292, 293, 294)

The polypeptide complex of any one of claims 290 to 294, wherein the antibody or antigen binding fragment thereof selected is from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).

### Claim 296 (depends on 290, 291, 292, 293, 294, 295)

The polypeptide complex of any one of claims 290 to 295, wherein the antibody or antigen binding fragment thereof is human or humanized.

### Claim 297 (depends on 290, 291, 292, 293, 294, 295, 296)

The polypeptide complex of any one of claims 290 to 296, wherein the antibody or antigen binding fragment thereof comprises an scFv or one or more camelid VHH antibodies.

### Claim 298 (depends on 290, 291, 292, 293, 294, 295, 296, 297)

The polypeptide complex of any one of claims 290 to 297, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: tumor associated antigens (TAA), tumor specific antigens (TSA), NKG2D ligands, γδ T cell receptor (TCR) ligands, and αβ TCR ligands.

### Claim 299 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298)

The polypeptide complex of any one of claims 290 to 298, wherein the antibody or antigen binding fragment thereof binds an antigen selected from the group consisting of: FRα, integrin, BCMA, B7-H3, B7-H6, CAIX, CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, CEA, CLDN6, CLDN18.2, CLL-1, CS-1, CSPG4, CTAGE1, DLL3, EGFR, EGFRvIII, EGP2, EGP40, EPCAM, EPHA2, ERBB4, FAP, FCRL5, AchR, GD2, GD3, GPC3, HER2, HER2 p95, IL-10Rα, IL-13Rα2, Kappa, LAGE-1A, Lambda, LeY, L1-CAM, MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, MelanA or MART1, SLN), MUC1, MUC16, MICA, MICB, NCAM, NY-ESO-1, PLAC1, PRAME, PSCA, PSMA, ROR1, SSX2, Survivin, TAG72, TEM1/CD248, TEM7R, TPBG, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, VEGFR2, and WT-1.

### Claim 300 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299)

The polypeptide complex of any one of claims 290 to 299, wherein the antibody or antigen binding fragment thereof binds BCMA, B7-H3, CD19, CD20, CD22, CD33, CD79A, CD79B, and/or EGFRvIII.

### Claim 301 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds BCMA.

### Claim 302 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds CD19.

### Claim 303 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds CD20 or CD22.

### Claim 304 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds B7-H3.

### Claim 305 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds CD33.

### Claim 306 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds CD79A.

### Claim 307 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds CD79B.

### Claim 308 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the antibody or antigen binding fragment thereof binds EGFRvIII, optionally wherein the antibody is EGFR806 or an antigen binding fragment thereof.

### Claim 309 (depends on 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300)

The polypeptide complex of any one of claims 290 to 300, wherein the multimerization domains localize extracellularly when of the first polypeptide and the second polypeptide are expressed.
